Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
- PMID: 19221498
- DOI: 10.4161/cc.8.6.7933
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Abstract
The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including those with breast cancer. We studied the activity of metformin against diverse molecular subtypes of breast cancer cell lines in vitro. Metformin showed biological activity against all estrogen receptor (ER) positive and negative, erbB2 normal and abnormal breast cancer cell lines tested. It inhibited cellular proliferation, reduced colony formation and caused partial cell cycle arrest at the G(1) checkpoint. Metformin did not induce apoptosis (as measured by DNA fragmentation and PARP cleavage) in luminal A, B or erbB2 subtype breast cancer cell lines. At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression with no changes in p27(kip1) or p21(waf1). It inhibited mitogen activated protein kinase (MAPK) and Akt activity, as well as the mammalian target of rapamycin (mTOR) in both ER positive and negative, erbB2-overexpressing and erbB2-normal expressing breast cancer cells. In erbB2-overexpressing breast cancer cell lines, metformin reduced erbB2 expression at higher concentrations, and at lower concentrations within the therapeutic range, it inhibited erbB2 tyrosine kinase activity evidenced by a reduction of phosphorylated erbB2 (P-erbB2) at both auto- and Src- phosphorylation sites. These data suggest that metformin may have potential therapeutic utility against ER positive and negative, erbB2-overexpressing and erbB2-normal expressing breast cancer cells.
Similar articles
-
Metformin induces unique biological and molecular responses in triple negative breast cancer cells.Cell Cycle. 2009 Jul 1;8(13):2031-40. doi: 10.4161/cc.8.13.8814. Epub 2009 Jul 21. Cell Cycle. 2009. PMID: 19440038
-
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.Int J Cancer. 2007 Jul 1;121(1):157-64. doi: 10.1002/ijc.22606. Int J Cancer. 2007. PMID: 17304506
-
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.Cell Cycle. 2011 Sep 1;10(17):2959-66. doi: 10.4161/cc.10.17.16359. Epub 2011 Sep 1. Cell Cycle. 2011. PMID: 21862872
-
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658
-
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.Biomolecules. 2019 Dec 9;9(12):846. doi: 10.3390/biom9120846. Biomolecules. 2019. PMID: 31835318 Free PMC article. Review.
Cited by
-
Metformin Restrains the Proliferation of CD4+ T Lymphocytes by Inducing Cell Cycle Arrest in Normo- and Hyperglycemic Conditions.Biomolecules. 2024 Jul 14;14(7):846. doi: 10.3390/biom14070846. Biomolecules. 2024. PMID: 39062560 Free PMC article.
-
Biochemical hallmarks-targeting antineoplastic nanotherapeutics.Bioact Mater. 2024 Jul 2;36:427-454. doi: 10.1016/j.bioactmat.2024.05.042. eCollection 2024 Jun. Bioact Mater. 2024. PMID: 39044728 Free PMC article. Review.
-
Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies.Pharmaceuticals (Basel). 2024 Mar 19;17(3):396. doi: 10.3390/ph17030396. Pharmaceuticals (Basel). 2024. PMID: 38543182 Free PMC article. Review.
-
Anticarcinogenic Effects of Gold Nanoparticles and Metformin Against MCF-7 and A549 Cells.Biol Trace Elem Res. 2024 Oct;202(10):4494-4507. doi: 10.1007/s12011-024-04090-y. Epub 2024 Feb 15. Biol Trace Elem Res. 2024. PMID: 38358644
-
Systematic Investigation of Dose-Dependent Protein Thermal Stability Changes to Uncover the Mechanisms of the Pleiotropic Effects of Metformin.ACS Pharmacol Transl Sci. 2024 Jan 9;7(2):467-477. doi: 10.1021/acsptsci.3c00298. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357277
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous